Implications of Anemia in Human Immunodeficiency Virus, Cancer, and Hepatitis C Virus
Author:
Open Access
- 15 November 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (s4) , S293-S296
Abstract
Anemia is a multifactorial problem in patients with human immunodeficiency virus (HIV) infection, cancer, and hepatitis C virus (HCV) infection. New insights regarding anemia symptoms and quality of life (QOL) have prompted reassessment of traditional triggers for anemia treatment to increase hemoglobin (Hb) and improve QOL. In HIV-positive patients, anemia is independently associated with disease progression and survival. Many HIV-positive patients receiving highly active antiretroviral therapy (HAART) still develop mild to moderate anemia and associated QOL impairment. Epoetin alfa effectively increases Hb and improves QOL in these patients. Many HIV-positive patients are coinfected with HCV. Standard HCV therapy (interferon alfa/ribavirin) can cause anemia that may result in treatment alterations and compromised virologic outcome. Epoetin alfa therapy in anemic HCV patients increases Hb levels and may provide other benefits. Neuroprotective effects of epoetin alfa in preclinical models of central nervous system disorders have recently been demonstrated, implying a new therapeutic role for this cytokine.Keywords
This publication has 32 references indexed in Scilit:
- Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapyCancer, 2002
- Rapid suppression of hematopoiesis by standard or pegylated interferon-αGastroenterology, 2002
- Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV doseJournal of Hepatology, 2002
- A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in ratsBritish Journal of Pharmacology, 2002
- Symptomatology of anemiaSeminars in Oncology, 2001
- Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort StudyThe Lancet, 2000
- Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhageEuropean Journal of Pharmacology, 2000
- Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicityNeuroscience Letters, 2000
- In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhageEuropean Journal of Pharmacology, 2000
- Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trialHepatology, 1997